Related references
Note: Only part of the references are listed.The proprotein convertase furin in cancer: more than an oncogene
Zongsheng He et al.
ONCOGENE (2022)
Role of Furin in Colon Cancer Stem Cells Malignant Phenotype and Expression of LGR5 and NANOG in KRAS and BRAF-Mutated Colon Tumors
Jean Descarpentrie et al.
CANCERS (2022)
Loss of ZNF677 expression is a predictive biomarker for lymph node metastasis in Middle Eastern Colorectal Cancer
Abdul K. Siraj et al.
SCIENTIFIC REPORTS (2021)
The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer
Zongsheng He et al.
ONCOGENE (2020)
Detecting Recurrence Following Lobectomy for Thyroid Cancer: Role of Thyroglobulin and Thyroglobulin Antibodies
Amit Ritter et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
POLE and POLD1 pathogenic variants in the proofreading domain in papillary thyroid cancer
Abdul K. Siraj et al.
ENDOCRINE CONNECTIONS (2020)
Loss of Proprotein Convertase Furin in Mammary Gland Impairs proIGF1R and proIR Processing and Suppresses Tumorigenesis in Triple Negative Breast Cancer
Zongsheng He et al.
CANCERS (2020)
Krupple-Like Factor 5 is a Potential Therapeutic Target and Prognostic Marker in Epithelial Ovarian Cancer
Abdul K. Siraj et al.
FRONTIERS IN PHARMACOLOGY (2020)
Prognostic significance of DNMT3A alterations in Middle Eastern papillary thyroid carcinoma
Abdul K. Siraj et al.
EUROPEAN JOURNAL OF CANCER (2019)
Germline POLE and POLD1 proofreading domain mutations in endometrial carcinoma from Middle Eastern region
Abdul K. Siraj et al.
CANCER CELL INTERNATIONAL (2019)
Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in Middle Eastern papillary thyroid cancer
Rong Bu et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Overexpression of PARP is an independent prognostic marker for poor survival in Middle Eastern breast cancer and its inhibition can be enhanced with embelin co-treatment
Abdul Khalid Siraj et al.
Oncotarget (2018)
Targeting proprotein convertases in furin-rich lung cancer cells results in decreased in vitro and in vivo growth
Daniel E. Bassi et al.
MOLECULAR CARCINOGENESIS (2017)
The proprotein convertase furin in tumour progression
Patricia Jaaks et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Furin promotes epithelial-mesenchymal transition in pancreatic cancer cells via Hippo-YAP pathway
Youli Zhang et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2017)
Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013
Hyeyeun Lim et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Systematic Review of Trends in the Incidence Rates of Thyroid Cancer
Joseph J. Wiltshire et al.
THYROID (2016)
The Proprotein Convertase Furin Contributes to Rhabdomyosarcoma Malignancy by Promoting Vascularization, Migration and Invasion
Patricia Jaaks et al.
PLOS ONE (2016)
Association Between BRAF V600E Mutation and Recurrence of Papillary Thyroid Cancer
Mingzhao Xing et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Effect of Furin inhibitor on lung adenocarcinoma cell growth and metastasis
Yong-Chao Ma et al.
CANCER CELL INTERNATIONAL (2014)
The Results of Selective Use of Radioactive Iodine on Survival and on Recurrence in the Management of Papillary Thyroid Cancer, Based on Memorial Sloan-Kettering Cancer Center Risk Group Stratification
Iain J. Nixon et al.
THYROID (2013)
The Association of the BRAFV600E Mutation With Prognostic Factors and Poor Clinical Outcome in Papillary Thyroid Cancer
Tae Hyuk Kim et al.
CANCER (2012)
The biology and therapeutic targeting of the proprotein convertases
Nabil G. Seidah et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Furin Overexpression Suppresses Tumor Growth and Predicts a Better Postoperative Disease-Free Survival in Hepatocellular Carcinoma
Ya-Hui Huang et al.
PLOS ONE (2012)
Transgenic Overexpression of the Proprotein Convertase Furin Enhances Skin Tumor Growth
Jian Fu et al.
NEOPLASIA (2012)
Assembly and Initial Characterization of a Panel of 85 Genomically Validated Cell Lines from Diverse Head and Neck Tumor Sites
Mei Zhao et al.
CLINICAL CANCER RESEARCH (2011)
Vía de señalización dependiente de la proteincinasa de activación mitogénica en el carcinoma papilar de tiroides. De las bases moleculares a la práctica clínica
Carles Zafon et al.
Endocrinologia y Nutricion (2009)
Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population
Jehad Abubaker et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Selective inhibition of proprotein convertases represses the metastatic potential of human colorectal tumor cells
Nathalie Scamuffa et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
A small molecule furin inhibitor inhibits cancer cell motility and invasiveness
Julia Coppola et al.
NEOPLASIA (2008)
Proprotein convertases: Master switches in the regulation of tumor growth and progression
DE Bassi et al.
MOLECULAR CARCINOGENESIS (2005)
X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization
RL Camp et al.
CLINICAL CANCER RESEARCH (2004)
Increased furin activity enhances the malignant phenotype of human head and neck cancer cells
DE Bassi et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
Furin inhibition results in absent or decreased invasiveness and tumorigenicity of human cancer cells
DE Bassi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
